pfizer_istock-458618835_no_limit_pictures--1

nono_limit_pictures / iStockphoto.com

30 January 2018Africa

Pfizer, patents and political quagmires

Shahan Islam said his enforcement efforts against generic producers often lead to counterarguments surrounding the price of Pfizer’s drugs and accusations that the company does not provide sufficient access to medicine for poorer people.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Fed Circ orders Teva to delist five patents from Orange Book

Sarepta wins $115M in patent dispute over muscular dystrophy drug

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

Foley & Lardner adds litigation and transaction expert in New York

‘A marathon and a sprint at the same time’: How we won $452m damages